Literature DB >> 24971357

A biopsychosocial profile of adult Canadians with and without chronic back disorders: a population-based analysis of the 2009-2010 Canadian Community Health Surveys.

Brenna Bath1, Catherine Trask2, Jesse McCrosky3, Josh Lawson2.   

Abstract

Chronic back disorders (CBD) are a significant public health concern. Profiling Canadians with CBD and the associated biopsychosocial factors at a national population level is important to understand the burden of this condition and how clinicians, health systems, and related policies might address this potentially growing problem. We performed a secondary analysis of the 2009 and 2010 Canadian Community Health Surveys to calculate prevalence and to better understand the differences between people with and without CBD. An estimated 20.2% of the adult Canadian population reports having back problems lasting for 6 months or more. Among people with CBD, there was significantly greater likelihood of living in a more rural or remote location, being Aboriginal, being a former or current smoker, being overweight, having other chronic health conditions, having greater activity limitations, having higher levels of stress, and having lower perceived mental health. People who were single/never married or had an ethnicity other than Caucasian or Aboriginal were less likely to report having CBD. These results contribute to a growing body of research in the area that may assist with strategic prioritization and tailoring of health promotion efforts and health services for people with CBD, particularly among vulnerable groups.

Entities:  

Mesh:

Year:  2014        PMID: 24971357      PMCID: PMC4058275          DOI: 10.1155/2014/919621

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


1. Introduction

Musculoskeletal disorders comprise a surprisingly large share of the nonfatal disease burden around the world. International data suggest that chronic pain states, such as chronic back disorders (CBD), present a burden at least as great as, or perhaps even greater than, conditions that are conventionally prioritised as public health concerns [1]. In a recent review of the global burden of 290 diseases and conditions, low back pain was found to be the leading cause of years lived with disability [2]. Musculoskeletal conditions, such as low back pain, are likely to increasingly dominate the picture of disability at a population level as the demographic structure of society changes. Low back pain and related disorders have a large societal and personal impact estimated to affect 50–85% of all people at some time in life [3]. The economic consequences of back disorders represent an enormous cost for society due to direct health-care utilization costs and indirect costs such as loss of productivity and lost wages [4]. In Canada, medical expenditures with respect to back disorders are estimated between $6 and $12 billion annually [5]. Although clinical practice guidelines suggest that recovery from an initial onset of acute back pain is usually rapid and complete [6], more recent evidence suggests that persisting (i.e., chronic) pain and disability for up to a year or more are not uncommon [7]. The biopsychosocial model is proposed as a means to more completely understand, evaluate, and manage disability attributed to persisting health conditions such as CBD [8-10]. This model draws on broader understanding of biological and psychosocial influences on the development and persistence of pain and disability; it does not reject a search for important pathology but rather shifts the emphasis to other components of the problem [11]. Even though back pain may start as a physical or biological problem, people with back pain and the health-care providers working with them often view the physical symptom through a series of psychological and social filters [9]. A social model explains disability as being primarily caused by oppressive social and economic conditions. In contrast, a biomedical model has an individual focus and assumes a direct link between pain, disease, and physical pathology. The biopsychosocial approach is a compromise between a purely biomedical and a purely social model of disability and reflects the concept that disability related to CBD should be viewed as a problem arising from the interaction between physical/biological (e.g., age, sex, and physical exposures), psychological (i.e., cognition, affect, and behavior), and social factors (i.e., social and cultural contexts) [8, 9, 12, 13]. The biopsychosocial model forms the basis of the World Health Organization's International Classification of Functioning, Disability, and Health (ICF) [14-16]. The ICF represents a comprehensive classification system that makes it possible to describe disability at a variety of biological, personal, or societal levels in the context of environmental factors that may either enhance or detract from overall health and wellness [14, 16]. The ICF provides a framework in which tissue damage may be a relatively small component of a musculoskeletal problem and acknowledges that psychological, social, and cultural contexts contribute to health outcomes including participation in social and other life activities [17]. A variety of biopsychosocial factors, including age, social support, depression, and other comorbidities, have been linked to persisting pain and disability in people with back disorders [13, 18–20]. In the context of CBD, psychological and social factors are thought to be just as important as (if not more important than) biomedical or physical factors [18, 19, 21]. Prior research using Canadian data has examined predictors of new-onset CBD [22], the association between CBD and depression [20], and self-reported health-care utilization among people with and without CBD [23]. However, to the best of our knowledge, investigation of both the prevalence of CBD and examination of the association of a range of biopsychosocial factors with CBD in a population-based sample of Canadian adults has yet to be done. Notably, much of the population-based back pain research internationally has focused on prevalence of back pain (using a range of case definitions) [24-26] or focused on a narrow subset of biopsychosocial factors, such as age, gender, depression, or occupational risk factors [24, 26–28]. Furthermore, there appears to be very few countrywide studies on CBD prevalence, particularly ones that consider a range of biopsychosocial factors [24]. Among 165 included studies in a systematic review of the global prevalence of low back pain, only 13 (7.9%) examined chronic (i.e., >3-month duration) or recurrent low back pain, and among those, only 2 studies had a nationally representative sample [20, 29]. However, neither nationally representative study examined CBD alone as the dependent variable of interest or profiled the biological, psychological, and social factors associated with CBD. Currie and colleagues focused on the relationship between CBD and depression [20]. Makela et al. investigated how a range of musculoskeletal disorders (including CBD) were associated with disability, but not the biopsychosocial factors associated with CBD [29]. Determining the prevalence of CBD and profiling its associated biological, psychological, and social factors at a national population level are important to understand the burden of this condition and how clinicians, health systems, and related policies might address this potentially growing public health problem. The aim of this study was to determine the prevalence of self-reported CBD and to profile the sociodemographics, comorbidities, perceived disability, and other health status indicators among people with CBD compared to people without CBD in the Canadian adult population.

2. Materials and Methods

2.1. Study Design and Data Source

We used data from Statistics Canada's 2009 and 2010 Canadian Community Health Surveys (CCHS). The CCHS was designed to provide a flexible survey instrument to address emerging health issues in Canada. It includes a range of content such as sociodemographics, health status, health behaviours, and many other determinants of health [30]. The CCHS is a cross-sectional study in which respondents are selected using a complex survey design with a two-phase stratified sampling plan intended to ensure adequate representation from each Canadian region.

2.2. Study Population

The CCHS targets Canadians aged 12 years and older living in private dwellings in all 10 provinces and 3 territories. The survey did not include people living on First Nations reserves or residents of institutional and some noninstitutional collectives (e.g., military bases, Canadian Armed Forces vessels, merchant and coast guard vessels, campgrounds, or parks). Approximately 130 000 Canadians were selected for the 2009 or 2010 survey, sampled from and representative of approximately 98% of the Canadian population aged 12 years and older. The participation rate of this survey was 72.3% [30]. The focus of our analysis was persons aged 18 years and older (N = 113 647). Of these adult respondents, 25 545 reported having a CBD. Ethical approval for data collection was completed by Statistics Canada (Government of Canada). Our access to this data was only through approved research data centers following a rigorous screening process and approval of the proposed research in order to use this deidentified data as well as vetting procedures to ensure confidentiality and protection of the subject.

2.3. Survey Data and Operational Definitions

The dependent variable was presence of CBD, using the survey question: “(Do you) have back problems, excluding fibromyalgia and arthritis?” This section of the survey is prefaced with the reminder: “Now I'd like to ask about certain chronic health conditions which (you) may have. We are interested in ‘long-term conditions' which are expected to last or have already lasted for 6 months or more and that have been diagnosed by a health professional.” A range of independent variables grouped into sociodemographic, lifestyle, and health characteristics were identified based on a review of the literature, clinical relevance, and data availability within the survey. The alignment of these variables with the biopsychosocial model was a further consideration for inclusion in the study. Further details regarding the description and categorization of the variables can be found in Table 1.
Table 1

Description of (independent) variables included in analysis.

Variable Description (if applicable) and categories
Sociodemographic characteristics
Age18–34 yrs; 35–49 yrs; 50–64 yrs; ≥65 yrs. Categories based on quartiles and clinical relevance
SexMale; female
EducationLess than secondary; secondary graduation; some postsecondary; postsecondary graduation
Income A StatsCan-derived variable addressing income adequacy. Quintile of adjusted ratio of total household income to the low income cut-off corresponding to household and community size. This variable was unavailable for some respondents, for example, in cases where the person most knowledgeable about the household could not be identified (N = 92,669)
ResidenceA StatsCan-derived variable. “Urban” residence includes communities with populations ≥10,000 people. “Rural” communities are disaggregated into subgroups or metropolitan influenced zones (MIZ) based on the size of commuting flows to any larger urban center [31]
EthnicityCaucasian; Aboriginal (i.e., North American Indian, Métis, or Inuit); other
Marital statusSingle; married or common law; widowed or separated or divorced
Body Mass Index (BMI)Derived from self-reported height and weight Underweight and normal (<25 kg/m2); overweight (25–29.9 kg/m2); obese (≥30 kg/m2) [32]

Lifestyle characteristics
Smoking statusNever smoked; former smoker; current smoker
Physical activity-transportation and leisureA StatsCan-derived variable combining leisure time and transportation-physical activity based on estimated total daily energy expenditure variables (kcal/kg/day): active; moderately active; inactive
Sedentary activity durationA StatsCan-derived variable of total number of hours per week spent in sedentary activities (excluding reading): 0–14 hours; 15–24 hours; 25–39 hours; 40 or more hours.* This variable was only available for respondents in the provinces of Newfoundland, Manitoba, and British Columbia (N = 22,380)

Health characteristics
Number of other comorbidities/chronic conditions Includes “long-term conditions” which are expected to last or have already lasted for 6 months or more and that have been diagnosed by a health professional. No other chronic conditions (other than CBD); 1 or 2 chronic conditions (other than CBD); 3 or more chronic conditions (other than CBD)
Type of other comorbiditiesPresence of top 5 chronic comorbidities associated with CBD: arthritis (excluding fibromyalgia); high blood pressure; migraine headaches; asthma; mood disorders (i.e., depression, bipolar disorder, mania, or dysthymia)
Perceived disability This variable, derived from the Health Utility Index (HUI) [33], considers whether pain prevents a person from performing activities of daily living. 5 categories: no pain or discomfort; pain prevents no activities; pain prevents a few activities; pain prevents some activities; pain prevents most activities
Depression probabilityA StatsCan-derived variable indicating the probability that the respondent would have been diagnosed as having experienced a major depressive episode in the past 12 months, if they had completed the long-form composite international diagnostic interview (CIDI) [34]. This variable was not available for respondents that completed the survey by proxy (N = 53,017)
Self-rated stressAbility to handle day-to-day demands: not at all/not very; a bit; quite a bit/extremely*
Self-rated mental healthIndicating the respondent's mental health status based on his/her own judgement: excellent/very good; good; fair/poor*
Self-rated overall healthIndicating the respondent's health status based on his/her own judgement or his/her proxy: excellent/very good; good; fair/poor*
Self-rated work stressIndicating level of stress encountered “most days at work”: not at all/not very; a bit; quite a bit/extremely.* This variable was only available for employed respondents (N = 69,992)

*Collapsing of these categories was performed to maintain equal-sized categories and consistent categorization for all variables of interest.

2.4. Statistical Analysis

The descriptive analysis included calculation of proportions over each of our independent variables (all categorical) for persons with and without CBD using a chi-squared test suitable for complex survey data to test whether each variable was distributed differently between those with and without CBD. Crude associations between each independent variable and CBD were further assessed using bivariate logistic regression. The strength of association was quantified with the odds ratio (OR) and 95% confidence interval (CI). In order to control for potential confounding, a multiple logistic regression model was developed. Due to the associations between many of our ordinal independent variables, a Goodman and Kruskal gamma was calculated between each pair of independent variables to determine their degrees of association. The regression model was then fitted using purposeful selection informed by statistical significance, clinical importance, potential and observed confounding effects, and the calculated gamma values. We also considered interaction terms: sex by age and sex by Health Utility Index (HUI) pain and function index. Of the interaction terms, only sex by age was retained. All analyses were performed using Stata 13 software with built-in survey data tools for probability weights and bootstrapping. Probability weights provided by Statistics Canada were used to account for unequal probability of selection, and bootstrap methods for robust variance estimation were employed using bootstrap weights provided by Statistics Canada in order to account for the complex survey design and to accurately estimate standard errors.

3. Results

Estimated CBD prevalence of 20.2% in the adult Canadian population was observed. Table 2 presents the results of our descriptive and bivariate analysis. When comparing adults with and without CBD, all of the sociodemographic, lifestyle, and health characteristics we examined were significantly different between these groups at the P < 0.05 level. Among those with CBD, a higher proportion were female compared to those who did not have CBD. Respondents with higher levels of educational attainment and higher income levels (i.e., higher income adequacy quintile) were less likely to report having CBD. People living in more rural and remote regions (i.e., moderate, weak, or no metropolitan influence zones (MIZ)) were more likely than urban or strongly influenced MIZ dwellers to report having CBD. Aboriginal respondents were more likely than Caucasians to report CBD, whereas people with “other” ethnicity were less likely than Caucasians to report CBD.
Table 2

Sociodemographic and lifestyle characteristics of adult Canadians with and without CBD.

ProportionsUnadjusted odds ratio
With CBD Without CBD P value (chi-square)OR (95% CI) P value
Age<0.001
 18–34 16.7% 31.8% Reference category
 35–49 28.0% 28.6% 1.87 (1.72–2.02) <0.001
 50–64 33.1% 24.0% 2.63 (2.44–2.83) <0.001
 65+ 22.3% 15.6% 2.71 (2.53–2.91) <0.001
Sex0.005
 Female 52.2% 50.5% Reference category
 Male 47.8% 49.5% 0.93 (0.88–0.98) 0.005
Education<0.001
 Less than secondary 19.2% 13.6% Reference category
 Secondary graduation 16.5% 17.2% 0.68 (0.63–0.74) <0.001
 Some postsecondary 7.4% 8.5% 0.62 (0.56–0.70) <0.001
 Postsecondary graduation 56.9% 60.7% 0.66 (0.62–0.71) <0.001
Income quintile<0.001
 1 24.2% 18.6% Reference category
 2 21.3% 19.7% 0.83 (0.76–0.90) <0.001
 3 18.9% 20.2% 0.72 (0.66–0.78) <0.001
 4 17.2% 20.7% 0.63 (0.58–0.69) <0.001
 5 18.4% 20.8% 0.68 (0.62–0.74) <0.001
MIZ<0.001
 Urban/metropolitan 81.1% 83.8% Reference category
 Rural strongly influenced 3.8% 3.9% 1.02 (0.91–1.14)0.749
 Rural moderately influenced 7.6% 6.2% 1.26 (1.16–1.37) <0.001
 Rural weak/uninfluenced + territories 7.5% 6.1% 1.28 (1.20–1.37) <0.001
Ethnicity<0.001
 Caucasian 84.0% 79.9% Reference category
 Aboriginal 4.2% 2.7% 1.46 (1.30–1.65) <0.001
 Other 11.8% 17.3% 0.64 (0.58–0.71) <0.001
Marital status<0.001
 Single 16.3% 24.6% Reference category
 Married + common law 65.7% 63.3% 1.57 (1.47–1.67) <0.001
 Widowed + separated + divorced 18.0% 12.0% 2.27 (2.09–2.46) <0.001
Smoking status<0.001
 Never smoked 30.7% 40.4% Reference category
 Former smoker 42.8% 39.1% 1.44 (1.35–1.53) <0.001
 Current smoker 26.5% 20.5% 1.70 (1.58–1.82) <0.001
BMI<0.001
 Underweight/normal 40.1% 50.1% Reference category
 Overweight 36.8% 33.2% 1.38 (1.30–1.47) <0.001
 Obese 23.1% 16.7% 1.72 (1.61–1.84) <0.001
Number of comorbidities<0.001
 None 27.5% 55.9% Reference category
 1-2 46.7% 36.3% 2.62 (2.46–2.79) <0.001
 3+ 25.8% 7.9% 6.67 (6.20–7.16) <0.001
Arthritis<0.001
 No 63.4% 88.6% Reference category
 Yes 36.6% 11.4% 4.48 (4.24–4.74) <0.001
High BP<0.001
 No 73.6% 83.4% Reference category
 Yes 26.4% 16.6% 1.80 (1.70–1.91) <0.001
Migraines<0.001
 No 81.7% 91.7% Reference category
 Yes 18.3% 8.3% 2.47 (2.30–2.66) <0.001
Asthma<0.001
 No 87.3% 93.2% Reference category
 Yes 12.7% 6.8% 2.01 (1.85–2.19) <0.001
Mood disorders<0.001
 No 86.9% 94.7% Reference category
 Yes 13.1% 5.3% 2.73 (2.52–2.95) <0.001
Physical activity-transportation and leisure<0.001
 Active 22.3% 28.0% Reference category
 Moderately active 23.3% 26.2% 1.11 (1.04–1.21) 0.008
 Inactive 54.3% 45.8% 1.48 (1.39–1.58) <0.001
Sedentary activity <0.001
 0 to 14 hours 21.9% 25.2% Reference category
 15 to 24 hours 29.2% 31.6% 1.06 (0.91–1.25)0.433
 25 to 39 hours 29.6% 27.4% 1.24 (1.07–1.45) 0.005
 40 or more hours 19.3% 15.9% 1.40 (1.18–1.66) <0.001
Perceived disability<0.001
 No pain or discomfort 53.5% 88.7% Reference category
 Pain prevents no activities 9.5% 3.8% 4.12 (3.73–4.55) <0.001
 Pain prevents a few activities 14.2% 3.7% 6.40 (5.84–7.01) <0.001
 Pain prevents some activities 12.7% 2.3% 9.03 (8.17–9.98) <0.001
 Pain prevents most activities 10.0% 1.5% 11.32 (9.99–12.82) <0.001
Depression scale predicted probability<0.001
 <0.9 90.5% 95.5% Reference category
 ≥0.9 9.5% 4.5% 2.24 (1.97–2.56) <0.001
Self-rated stress<0.001
 Not at all/not very 28.0% 35.9% Reference category
 A bit 41.0% 42.2% 1.25 (1.18–1.32) <0.001
 Quite a bit/extremely 31.1% 21.9% 1.83 (1.71–1.95) <0.001
Self-rated mental health<0.001
 Excellent/very good 62.2% 76.5% Reference category
 Good 27.4% 19.4% 1.74 (1.64–1.85) <0.001
 Fair/poor 10.3% 4.1% 3.08 (2.82–3.38) <0.001
Self-rated overall health<0.001
 Excellent/very good 41.1% 64.1% Reference category
 Good 34.1% 27.1% 1.96 (1.85–2.08) <0.001
 Fair/poor 24.8% 8.7% 4.43 (4.12–4.75) <0.001
Self-rated work stress<0.001
 Not at all/not very 22.8% 29.0% Reference category
 A bit 39.2% 42.2% 1.18 (1.08–1.29) <0.001
 Quite a bit/extremely 38.1% 28.8% 1.68 (1.53–1.84) <0.001

MIZ: metropolitan influenced zone; BMI: Body Mass Index; BP: blood pressure.

The top 5 self-reported chronic comorbidities among people with CBD were arthritis, high blood pressure, migraines, asthma, and mood disorders. Respondents who reported having any of these other chronic conditions were more likely to report having CBD. Also, people reporting having 1-2 or 3 or more chronic health conditions (other than CBD) were more likely to report having CBD. Lower physical activity levels and higher time spent being sedentary were associated with a greater likelihood of reporting CBD. People with CBD were more likely than those without CBD to report having activity limitations due to pain. Table 3 presents our multivariate model along with the unadjusted (bivariate) logistic regression results for each variable included in the model. All variables except residence in a strongly influenced MIZ were significant in the bivariate analysis. In the adjusted model, all variables were found to be significant except sex, education (all levels), residence in strongly or moderately influenced MIZ, being obese, and physical activity. Due to an observed interaction between sex and age category, we present a graph of predicted probability of CBD over age for each sex in Figure 1.
Table 3

Multivariate model of adult Canadians with and without CBD.

Odds ratio for CBD
UnadjustedAdjusted
OR (95% CI) P valueOR (95% CI) P value
Age
 18–34Reference categoryReference category
 35–49 1.87 (1.73–2.01) <0.001 1.25 (1.12–1.4) <0.001
 50–64 2.63 (2.45–2.82) <0.001 1.36 (1.21–1.53) <0.001
 65+ 2.71 (2.54–2.9) <0.001 1.35 (1.2–1.53) <0.001
Sex
 FemaleReference categoryReference category
 Male 0.93 (0.89–0.98) 0.0050.98 (0.87–1.1)0.739
Age ∗ male
 18–34Reference category
 35–49 1.22 (1.04–1.42) 0.012
 50–64 1.25 (1.06–1.48) 0.009
 65+0.93 (0.8–1.09)0.384
Education
 Less than secondaryReference categoryReference category
 Secondary graduation 0.68 (0.63–0.74) <0.0010.99 (0.89–1.09)0.803
 Some postsecondary 0.62 (0.56–0.69) <0.0010.93 (0.82–1.06)0.267
 Postsecondary graduation 0.66 (0.62–0.71) <0.0011.01 (0.93–1.09)0.819
MIZ
 Urban/metropolitan Reference categoryReference category
 Rural strongly influenced1.02 (0.91–1.15)0.7490.95 (0.83–1.08)0.446
 Rural moderately influenced 1.26 (1.17–1.36) <0.0011.08 (0.98–1.19)0.102
 Rural weak/uninfluenced + territories 1.28 (1.19–1.38) <0.001 1.09 (1–1.18) 0.046
Ethnicity
 CaucasianReference categoryReference category
 Aboriginal 1.46 (1.3–1.65) <0.001 1.23 (1.06–1.43) 0.007
 Other 0.64 (0.58–0.71) <0.001 0.84 (0.76–0.94) 0.002
Marital status
 SingleReference categoryReference category
 Married + common law 1.57 (1.47–1.67) <0.001 1.15 (1.06–1.25) 0.001
 Widowed + separated + divorced 2.27 (2.09–2.46) <0.001 1.17 (1.05–1.31) 0.004
Smoking status
 Never smokedReference categoryReference category
 Former smoker 1.44 (1.36–1.53) <0.001 1.15 (1.07–1.23) <0.001
 Current smoker 1.7 (1.58–1.81) <0.001 1.39 (1.29–1.51) <0.001
BMI
 Underweight/normalReference categoryReference category
 Overweight 1.38 (1.31–1.47) <0.001 1.11 (1.04–1.19) 0.001
 Obese 1.72 (1.61–1.83) <0.0011.02 (0.95–1.1)0.576
Number of comorbidities
 NoneReference categoryReference category
 1-2 2.62 (2.47–2.78) <0.001 1.78 (1.67–1.91) <0.001
 3+ 6.67 (6.21–7.16) <0.001 2.68 (2.42–2.97) <0.001
Physical activity-transportation + leisure
 ActiveReference categoryReference category
 Moderately active 1.11 (1.03–1.2) 0.0080.94 (0.87–1.03)0.19
 Inactive 1.48 (1.39–1.58) <0.0010.98 (0.92–1.06)0.677
Perceived disability
 No pain or discomfortReference categoryReference category
 Pain prevents no activities 4.12 (3.74–4.54) <0.001 3.21 (2.89–3.56) <0.001
 Pain prevents a few activities 6.4 (5.87–6.98) <0.001 4.67 (4.22–5.17) <0.001
 Pain prevents some activities 9.03 (8.12–10.03) <0.001 5.84 (5.19–6.56) <0.001
 Pain prevents most activities 11.32 (10.12–12.65) <0.001 6.35 (5.56–7.25) <0.001
Self-rated stress
 Not at all/not veryReference categoryReference category
 A bit 1.25 (1.17–1.33) <0.001 1.18 (1.1–1.27) <0.001
 Quite a bit/extremely 1.83 (1.71–1.95) <0.001 1.33 (1.23–1.45) <0.001
Self-rated mental health
 Excellent/very goodReference categoryReference category
 Good 1.74 (1.64–1.85) <0.001 1.22 (1.14–1.32) <0.001
 Fair/poor 3.08 (2.82–3.37) <0.001 1.29 (1.14–1.45) <0.001

MIZ: metropolitan influenced zone; BMI: Body Mass Index; BP: blood pressure.

Figure 1

Predicted probabilities of CBD by age and sex.

4. Discussion

The aim of this study was to determine the prevalence of CBD and to profile a range of variables, framed by a biopsychosocial model, among people with CBD compared to people without CBD in the Canadian adult population. Profiling those with CBD and its associated biological, psychological, and social factors at a national population level is important to understand the burden of this condition and how clinicians, health systems, and related policies might address this potentially growing public health problem. We found that a substantial proportion of adult Canadians reported having back problems lasting for 6 months or more. Women had higher prevalence of CBD than men overall, but the relationship depended on age. The prevalence of CBD among men in our sample followed the typical clinical pattern described in the literature, whereby prevalence is highest in middle-aged groups (e.g., 50–64 years) and tapers off with increasing age [22]. However, this pattern was not evident among women with the prevalence of CBD among women aged 65 or more being similar to that among women aged 50–64 years. Among people with CBD, there was significantly greater likelihood of living in a more rural or remote location, being Aboriginal, being a former or current smoker, being overweight, having other chronic health conditions, having increased levels of perceived pain and activity limitations, having higher levels of stress, and having lower perceived mental health. People who were single/never married or had an ethnicity other than Caucasian or Aboriginal were less likely to report having CBD. Comparison of studies on prevalence of back disorders is challenging due to heterogeneity across research methods, case definitions, and study populations [26]. Back disorders include a large heterogeneous group of clinical and etiological entities [35]. The most common descriptor used in epidemiological studies is “low back pain” which can represent a variety of underlying clinical conditions and duration of symptoms. Given these issues, it is unsurprising that population-based estimates of low back pain prevalence vary substantially worldwide. An estimated 15% to 20% of adults experience back pain during a single year, and 50% to 80% experience at least one episode of back pain during their lifetime [3, 24]. The sex differences we found in our study are similar to those of a recent systematic review, which found that prevalence of low back pain was higher in women overall and among older women [24]. Even though other research has shown that women are more likely to develop chronic low back pain and have higher perceived disability due to back pain [36], we did not find that sex was associated with perceived activity limitations due to pain (i.e., HUI pain and function). However, a large proportion of people with CBD reported having some degree of activity limitations, with 10.0% reporting “most” activities were limited due to pain. This finding is similar to another study in which 10.5% of an adult Australian sample reported experiencing high disability due to low back pain [25]. Further to this, a Canadian study found that musculoskeletal conditions in general were the most prevalent medical condition (46.1%) to which activity and participation limitations were attributed [37]. There are a number of environmental, personal, and lifestyle factors that could potentially influence the onset and course of back pain. An inverse relationship between social status and educational attainment with the occurrence of back pain has been well documented in prior research [26] and confirmed in our study. Similar to our findings, Zvolensky et al. found that people with CBD were more likely to smoke than those without, an association that remained significant after adjusting for a variety of sociodemographic factors and the presence of mood or anxiety disorders [38]. The relationship between CBD and being overweight or obese and physical activity levels is equivocal as yet [39, 40], a finding echoed by our results. Psychological factors such as depression have been shown to be associated with having CBD and the development of chronic back pain [20, 41]. Although “depression” was not included as a variable in our final adjusted model, self-rated mental health and perceived stress were. Further to depression, there are a number of other comorbidities that we found to be associated with CBD. A systematic review of comorbidities and low back pain found a positive association between a number of other disorders (e.g., migraines/headaches, respiratory, and cardiovascular conditions); however, the nature of the relationship between these comorbidities and CBD is unclear [42]. Not only the presence of certain chronic conditions but also the number of other conditions was highly associated with having CBD. Thus, the issue of multimorbidity is likely an important consideration when examining health-care policies and services related to CBD. To the best of our knowledge, the higher CBD prevalence in rural and Aboriginal Canadian populations has not previously been reported; however, these findings are not surprising given the well-documented health disparities in these populations [43]. Although higher rates of arthritis are documented in Aboriginal Canadians [43, 44], no studies have focused solely on CBD. The higher prevalence of CBD among Aboriginal people and rural and remote residents calls for further investigation into whether these groups have different biopsychosocial characteristics and thus perhaps different needs in terms of health care or health promotion related to CBD. Research examining CBD among Aboriginal people in Australia, for example, found that the condition can be profoundly disabling and that issues of sex, cultural obligations, and emotional consequences are important considerations for health care [45]. The results of this study should be considered in light of a number of limitations. The cross-sectional design does not permit conclusions regarding the direction of the observed associations nor does it capture the clinical course and lifetime progression of CBD. However, the national population cross-sectional approach we used in this study does allow us to capture not only new-onset or incident CBD but also those people with existing and potentially longstanding CBD. The classification of having CBD was derived through self-report and may have been variably interpreted by respondents. Back disorders include a large group of clinical and etiological entities and there is no “gold standard” for clinical classification and diagnosis for many of these conditions. The International Classification of Diseases- (ICD-) 10 system does not have an adequate and distinct diagnostic code for chronic pain or CBD [1]. The development and international acceptance of a standard case definition for CBD would help to move the research and policy agenda for CBD forward. Although we attempted to examine a range of independent variables guided by the biopsychosocial model and identified based on a review of the literature, clinical relevance, and data availability within the survey, not all relevant variables may have been considered. Specifically, this study did not examine health-care utilization or other economic impact factors. However, many people with CBD may not necessarily seek health care for their condition or seek care during the time frame specified by the survey. In addition, CCHS data are only available for Aboriginal people living off of reserves and this analysis is limited to the categories “Aboriginal,” “Caucasian,” and “other” which are not homogeneous groups. Finally, the self-reported data on which this study is based may underestimate the prevalence of some behavioural risk factors, such as overweight, obesity, and smoking and overestimate the prevalence of physical activity [46].

5. Conclusion

This study provides insight into the magnitude and nature of CBD in Canada using a nationally representative sample. We found that a substantial proportion (20.2%) of adult Canadians report having back problems lasting for 6 months or more. A variety of modifiable and nonmodifiable sociodemographic, health, and lifestyle factors were significantly associated with having CBD. Our results demonstrated that some biological, psychological, and sociodemographic factors are more common among Canadians with CBD than those without. Regardless of causality, understanding the unique characteristics of people with CBD can help develop more appropriate educational materials or programs (for prevention or management) and help clinicians consider potential additional health needs or potential management contraindications presented by comorbidities. Consideration of factors such as rural and remote residence, Aboriginal ethnicity, and multimorbidity may have implications for ensuring equitable access to appropriate health services and health promotion efforts. Further research should examine CBD in these potentially vulnerable groups and examine issues of health-care utilization, access, and unmet health needs.
  38 in total

1.  Chapter 3. European guidelines for the management of acute nonspecific low back pain in primary care.

Authors:  Maurits van Tulder; Annette Becker; Trudy Bekkering; Alan Breen; Maria Teresa Gil del Real; Allen Hutchinson; Bart Koes; Even Laerum; Antti Malmivaara
Journal:  Eur Spine J       Date:  2006-03       Impact factor: 3.134

2.  Use of the International Classification of Functioning, Disability and Health: a literature survey.

Authors:  Jennifer Jelsma
Journal:  J Rehabil Med       Date:  2009-01       Impact factor: 2.912

3.  A population-based analysis of healthcare utilization of persons with back disorders: results from the Canadian Community Health Survey 2000-2001.

Authors:  Kim-Lian Lim; Philip Jacobs; Scott Klarenbach
Journal:  Spine (Phila Pa 1976)       Date:  2006-01-15       Impact factor: 3.468

Review 4.  What predicts outcome in non-operative treatments of chronic low back pain? A systematic review.

Authors:  Tina Wessels; Maurits van Tulder; Tanja Sigl; Thomas Ewert; Heribert Limm; Gerold Stucki
Journal:  Eur Spine J       Date:  2006-03-31       Impact factor: 3.134

5.  Low back pain: a twentieth century health care enigma.

Authors:  G Waddell
Journal:  Spine (Phila Pa 1976)       Date:  1996-12-15       Impact factor: 3.468

6.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II.

Authors:  Reva C Lawrence; David T Felson; Charles G Helmick; Lesley M Arnold; Hyon Choi; Richard A Deyo; Sherine Gabriel; Rosemarie Hirsch; Marc C Hochberg; Gene G Hunder; Joanne M Jordan; Jeffrey N Katz; Hilal Maradit Kremers; Frederick Wolfe
Journal:  Arthritis Rheum       Date:  2008-01

Review 7.  Epidemiology and risk factors for spine pain.

Authors:  Devon I Rubin
Journal:  Neurol Clin       Date:  2007-05       Impact factor: 3.806

8.  Predictors of back pain in a general population cohort.

Authors:  Jacek A Kopec; Eric C Sayre; John M Esdaile
Journal:  Spine (Phila Pa 1976)       Date:  2004-01-01       Impact factor: 3.468

9.  The prognosis of acute and persistent low-back pain: a meta-analysis.

Authors:  Luciola da C Menezes Costa; Christopher G Maher; Mark J Hancock; James H McAuley; Robert D Herbert; Leonardo O P Costa
Journal:  CMAJ       Date:  2012-05-14       Impact factor: 8.262

10.  Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.

Authors:  Theo Vos; Abraham D Flaxman; Mohsen Naghavi; Rafael Lozano; Catherine Michaud; Majid Ezzati; Kenji Shibuya; Joshua A Salomon; Safa Abdalla; Victor Aboyans; Jerry Abraham; Ilana Ackerman; Rakesh Aggarwal; Stephanie Y Ahn; Mohammed K Ali; Miriam Alvarado; H Ross Anderson; Laurie M Anderson; Kathryn G Andrews; Charles Atkinson; Larry M Baddour; Adil N Bahalim; Suzanne Barker-Collo; Lope H Barrero; David H Bartels; Maria-Gloria Basáñez; Amanda Baxter; Michelle L Bell; Emelia J Benjamin; Derrick Bennett; Eduardo Bernabé; Kavi Bhalla; Bishal Bhandari; Boris Bikbov; Aref Bin Abdulhak; Gretchen Birbeck; James A Black; Hannah Blencowe; Jed D Blore; Fiona Blyth; Ian Bolliger; Audrey Bonaventure; Soufiane Boufous; Rupert Bourne; Michel Boussinesq; Tasanee Braithwaite; Carol Brayne; Lisa Bridgett; Simon Brooker; Peter Brooks; Traolach S Brugha; Claire Bryan-Hancock; Chiara Bucello; Rachelle Buchbinder; Geoffrey Buckle; Christine M Budke; Michael Burch; Peter Burney; Roy Burstein; Bianca Calabria; Benjamin Campbell; Charles E Canter; Hélène Carabin; Jonathan Carapetis; Loreto Carmona; Claudia Cella; Fiona Charlson; Honglei Chen; Andrew Tai-Ann Cheng; David Chou; Sumeet S Chugh; Luc E Coffeng; Steven D Colan; Samantha Colquhoun; K Ellicott Colson; John Condon; Myles D Connor; Leslie T Cooper; Matthew Corriere; Monica Cortinovis; Karen Courville de Vaccaro; William Couser; Benjamin C Cowie; Michael H Criqui; Marita Cross; Kaustubh C Dabhadkar; Manu Dahiya; Nabila Dahodwala; James Damsere-Derry; Goodarz Danaei; Adrian Davis; Diego De Leo; Louisa Degenhardt; Robert Dellavalle; Allyne Delossantos; Julie Denenberg; Sarah Derrett; Don C Des Jarlais; Samath D Dharmaratne; Mukesh Dherani; Cesar Diaz-Torne; Helen Dolk; E Ray Dorsey; Tim Driscoll; Herbert Duber; Beth Ebel; Karen Edmond; Alexis Elbaz; Suad Eltahir Ali; Holly Erskine; Patricia J Erwin; Patricia Espindola; Stalin E Ewoigbokhan; Farshad Farzadfar; Valery Feigin; David T Felson; Alize Ferrari; Cleusa P Ferri; Eric M Fèvre; Mariel M Finucane; Seth Flaxman; Louise Flood; Kyle Foreman; Mohammad H Forouzanfar; Francis Gerry R Fowkes; Richard Franklin; Marlene Fransen; Michael K Freeman; Belinda J Gabbe; Sherine E Gabriel; Emmanuela Gakidou; Hammad A Ganatra; Bianca Garcia; Flavio Gaspari; Richard F Gillum; Gerhard Gmel; Richard Gosselin; Rebecca Grainger; Justina Groeger; Francis Guillemin; David Gunnell; Ramyani Gupta; Juanita Haagsma; Holly Hagan; Yara A Halasa; Wayne Hall; Diana Haring; Josep Maria Haro; James E Harrison; Rasmus Havmoeller; Roderick J Hay; Hideki Higashi; Catherine Hill; Bruno Hoen; Howard Hoffman; Peter J Hotez; Damian Hoy; John J Huang; Sydney E Ibeanusi; Kathryn H Jacobsen; Spencer L James; Deborah Jarvis; Rashmi Jasrasaria; Sudha Jayaraman; Nicole Johns; Jost B Jonas; Ganesan Karthikeyan; Nicholas Kassebaum; Norito Kawakami; Andre Keren; Jon-Paul Khoo; Charles H King; Lisa Marie Knowlton; Olive Kobusingye; Adofo Koranteng; Rita Krishnamurthi; Ratilal Lalloo; Laura L Laslett; Tim Lathlean; Janet L Leasher; Yong Yi Lee; James Leigh; Stephen S Lim; Elizabeth Limb; John Kent Lin; Michael Lipnick; Steven E Lipshultz; Wei Liu; Maria Loane; Summer Lockett Ohno; Ronan Lyons; Jixiang Ma; Jacqueline Mabweijano; Michael F MacIntyre; Reza Malekzadeh; Leslie Mallinger; Sivabalan Manivannan; Wagner Marcenes; Lyn March; David J Margolis; Guy B Marks; Robin Marks; Akira Matsumori; Richard Matzopoulos; Bongani M Mayosi; John H McAnulty; Mary M McDermott; Neil McGill; John McGrath; Maria Elena Medina-Mora; Michele Meltzer; George A Mensah; Tony R Merriman; Ana-Claire Meyer; Valeria Miglioli; Matthew Miller; Ted R Miller; Philip B Mitchell; Ana Olga Mocumbi; Terrie E Moffitt; Ali A Mokdad; Lorenzo Monasta; Marcella Montico; Maziar Moradi-Lakeh; Andrew Moran; Lidia Morawska; Rintaro Mori; Michele E Murdoch; Michael K Mwaniki; Kovin Naidoo; M Nathan Nair; Luigi Naldi; K M Venkat Narayan; Paul K Nelson; Robert G Nelson; Michael C Nevitt; Charles R Newton; Sandra Nolte; Paul Norman; Rosana Norman; Martin O'Donnell; Simon O'Hanlon; Casey Olives; Saad B Omer; Katrina Ortblad; Richard Osborne; Doruk Ozgediz; Andrew Page; Bishnu Pahari; Jeyaraj Durai Pandian; Andrea Panozo Rivero; Scott B Patten; Neil Pearce; Rogelio Perez Padilla; Fernando Perez-Ruiz; Norberto Perico; Konrad Pesudovs; David Phillips; Michael R Phillips; Kelsey Pierce; Sébastien Pion; Guilherme V Polanczyk; Suzanne Polinder; C Arden Pope; Svetlana Popova; Esteban Porrini; Farshad Pourmalek; Martin Prince; Rachel L Pullan; Kapa D Ramaiah; Dharani Ranganathan; Homie Razavi; Mathilda Regan; Jürgen T Rehm; David B Rein; Guiseppe Remuzzi; Kathryn Richardson; Frederick P Rivara; Thomas Roberts; Carolyn Robinson; Felipe Rodriguez De Leòn; Luca Ronfani; Robin Room; Lisa C Rosenfeld; Lesley Rushton; Ralph L Sacco; Sukanta Saha; Uchechukwu Sampson; Lidia Sanchez-Riera; Ella Sanman; David C Schwebel; James Graham Scott; Maria Segui-Gomez; Saeid Shahraz; Donald S Shepard; Hwashin Shin; Rupak Shivakoti; David Singh; Gitanjali M Singh; Jasvinder A Singh; Jessica Singleton; David A Sleet; Karen Sliwa; Emma Smith; Jennifer L Smith; Nicolas J C Stapelberg; Andrew Steer; Timothy Steiner; Wilma A Stolk; Lars Jacob Stovner; Christopher Sudfeld; Sana Syed; Giorgio Tamburlini; Mohammad Tavakkoli; Hugh R Taylor; Jennifer A Taylor; William J Taylor; Bernadette Thomas; W Murray Thomson; George D Thurston; Imad M Tleyjeh; Marcello Tonelli; Jeffrey A Towbin; Thomas Truelsen; Miltiadis K Tsilimbaris; Clotilde Ubeda; Eduardo A Undurraga; Marieke J van der Werf; Jim van Os; Monica S Vavilala; N Venketasubramanian; Mengru Wang; Wenzhi Wang; Kerrianne Watt; David J Weatherall; Martin A Weinstock; Robert Weintraub; Marc G Weisskopf; Myrna M Weissman; Richard A White; Harvey Whiteford; Steven T Wiersma; James D Wilkinson; Hywel C Williams; Sean R M Williams; Emma Witt; Frederick Wolfe; Anthony D Woolf; Sarah Wulf; Pon-Hsiu Yeh; Anita K M Zaidi; Zhi-Jie Zheng; David Zonies; Alan D Lopez; Christopher J L Murray; Mohammad A AlMazroa; Ziad A Memish
Journal:  Lancet       Date:  2012-12-15       Impact factor: 79.321

View more
  13 in total

1.  Case Report: Using a Remote Presence Robot to Improve Access to Physical Therapy for People with Chronic Back Disorders in an Underserved Community.

Authors:  Stacey Lovo Grona; Brenna Bath; Luis Bustamante; Ivar Mendez
Journal:  Physiother Can       Date:  2017       Impact factor: 1.037

2.  Factors Associated with Reduced Perceived Access to Physiotherapy Services among People with Low Back Disorders.

Authors:  Brenna Bath; Megan Jakubowski; Darren Mazzei; Jessica McRae; Natalie McVittie; Sarah Stewart; Stacey Lovo Grona
Journal:  Physiother Can       Date:  2016       Impact factor: 1.037

3.  Get 'Er Done: Experiences of Canadian Farmers Living with Chronic Low Back Disorders.

Authors:  Brenna Bath; Bryna Jaindl; Lorenne Dykes; Jason Coulthard; Jessica Naylen; Noelle Rocheleau; Lynne Clay; Muhammad I Khan; Catherine Trask
Journal:  Physiother Can       Date:  2019       Impact factor: 1.037

4.  Mapping the Physiotherapy Profession in Saskatchewan: Examining Rural versus Urban Practice Patterns.

Authors:  Brenna Bath; Jeffery Gabrush; Rachel Fritzler; Nathan Dickson; Derek Bisaro; Kyla Bryan; Tayyab I Shah
Journal:  Physiother Can       Date:  2015-08       Impact factor: 1.037

5.  Chiropractic integration within a community health centre: a cost description and partial analysis of cost-utility from the perspective of the institution.

Authors:  Peter C Emary; Amy L Brown; Douglas F Cameron; Alexander F Pessoa
Journal:  J Can Chiropr Assoc       Date:  2019-08

6.  Walking away from back pain: one step at a time - a community-based randomised controlled trial.

Authors:  Stephan Milosavljevic; Lynne Clay; Brenna Bath; Catherine Trask; Erika Penz; Sam Stewart; Paul Hendrick; G David Baxter; Deirdre A Hurley; Suzanne M McDonough
Journal:  BMC Public Health       Date:  2015-02-13       Impact factor: 3.295

7.  Biopsychosocial predictors of short-term success among people with low back pain referred to a physiotherapy spinal triage service.

Authors:  Brenna Bath; Stacey Lovo Grona
Journal:  J Pain Res       Date:  2015-04-23       Impact factor: 3.133

8.  Stable prevalence of chronic back disorders across gender, age, residence, and physical activity in Canadian adults from 2007 to 2014.

Authors:  Adriana Angarita-Fonseca; Catherine Trask; Tayyab Shah; Brenna Bath
Journal:  BMC Public Health       Date:  2019-08-15       Impact factor: 3.295

9.  Experience of patients and practitioners with a team and technology approach to chronic back disorder management.

Authors:  Stacey Lovo; L Harrison; M E O'Connell; C Trask; B Bath
Journal:  J Multidiscip Healthc       Date:  2019-10-18

10.  Advancing Interprofessional Primary Health Care Services in Rural Settings for People with Chronic Low Back Disorders: Protocol of a Community-Based Randomized Controlled Trial.

Authors:  Brenna Bath; Stacey Lovo Grona; Stephan Milosavljevic; Nazmi Sari; Biaka Imeah; Megan E O'Connell
Journal:  JMIR Res Protoc       Date:  2016-11-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.